Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.50 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.45 |
| ▸ | YAP1 | P46937 | 1/20 | 0.43 |
| ▸ | STS | P08842 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25957593 | 0.93 | GPR119 (0.47) | GPR119JAK2JAK1DPP4USP30 | |
| SCHEMBL28686452 | 0.93 | GPR119 (0.47) | GPR119JAK2JAK1DPP4USP30 | |
| SCHEMBL22765085 | 0.93 | GPR119 (0.47) | GPR119JAK2JAK1DPP4USP30 | |
| SCHEMBL29440526 | 0.93 | GPR119 (0.47) | GPR119JAK2JAK1DPP4USP30 | |
| SCHEMBL31291044 | 0.93 | GPR119 (0.47) | GPR119JAK2JAK1DPP4USP30 | |
| SCHEMBL31346185 | 0.93 | GPR119 (0.54) | GPR119JAK2JAK1DPP4USP30 | |
| SCHEMBL30543812 | 0.91 | GPR119 (0.48) | GPR119JAK2JAK1DPP4USP30 | |
| SCHEMBL31291132 | 0.91 | GPR119 (0.48) | GPR119JAK2JAK1DPP4USP30 | |
| SCHEMBL25957732 | 0.90 | GPR119 (0.50) | GPR119JAK2JAK1DPP4USP30 | |
| SCHEMBL25339536 | 0.90 | GPR119 (0.52) | GPR119JAK2JAK1DPP4USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171399-A1 | PYRROLIDINE COMPOUNDS | ELI LILLY AND COMPANY | 2025-05-29 | — | — | US | disclosed |
| CN-118974013-A | Pyrrolidine compounds | 伊莱利利公司 | 2024-11-15 | — | — | CN | disclosed |
| WO-2023146785-A1 | PYRROLIDINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146785-A1 | PYRROLIDINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171399-A1 | PYRROLIDINE COMPOUNDS | SDHA, GMPS, SDHB | GPR119 3539/4885JAK2 112/4885JAK1 986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.